Research of features of development of epidemiological situation on lymphogranulematosis in Ukraine

Authors

DOI:

https://doi.org/10.15587/2519-4852.2020.201570

Keywords:

epidemiology of lymphogranulomatosis, lymphogranulomatosis, lymphomas, oncohematology, Hodgkin disease

Abstract

The aim. To analyse the peculiarities of the epidemiological situation on lymphogranulomatosis in the country during 2012-2018.

Materials and methods. The studies used data from the National Cancer Registry for 2012-2018. Historical, analytical, comparative, systemic, logical, hypothetical-deductive, mathematical-statistical, as well as methods of epidemiological studies were used.

Results. It was established that morbidity and mortality of the adult and children's population from lymphogranulomatosis, expressed in absolute terms during 2012-2018 in Ukraine decreased. Thus, the number of patients with lymphogranulomatosis in 2012 compared with the data in 2018 decreased by 26.9 %, and mortality – by 41.2 %, among children – by 37.7 % and 25.0 %. All absolute indicators were complex in terms of the nature of the changes, with peak values in 2015 and 2018 (incidence among adults), as well as in 2016 (mortality among adults) and in 2015 (incidence of children). At the same time, not a single indicator reached or exceeded the value of the 2012, with the exception of data on the incidence of children with lymphogranulomatosis in 2015 (an increase of 11.8 % compared with the previous 2014). It is gratifying that after 2015, the incidence rates of children with Hodgkin's disease have steadily declined. It was proved that women prevailed taken together indicators of morbidity (53.4 %), and in the mortality structure, on the contrary, the proportion ( %) of women was less (43.0 %). Among the children's contingent of patients, there were more men (53.0 %). According to the analysis of the relative incidence rates among men, it was found that their average value (2.29 per 100 thousand of the population in Ukraine) did not exceed the corresponding data of world epidemiology (2.3 per 100 thousand of the population of indicators) for lymphogranulomatosis. Among women, the average incidence rate (2.46 per 100 thousand of the population) significantly exceeded the corresponding world indicators (1.9 per 100 thousand of the population). The average value of the indicators of relative mortality from lymphogranulomatosis, which we calculated for 2012-2018 amounted to 0.69 for men and 0.47 for women per 100 thousand people against world figures of 0.4 and 0.3, respectively. Thus, we can conclude that the level of male mortality in Ukraine from lymphogranulomatosis was 1.7 times higher than the corresponding world indicators and 1.6 times higher for the female population.

Conclusions. From 2012 to 2018, Ukraine was able to reduce morbidity and mortality rates significantly, expressed in absolute data. At the same time, with regard to relative indicators, the fact of an increase in the incidence among women, as well as mortality from lymphogranulomatosis among adult patients causes our concern. This allows us to conclude that it is necessary to implement early diagnosis programs and chemotherapy regimens further, which can increase the 5-year survival of patients, as well as achieve stable and long-term remission in these patients.

Author Biographies

Marta Matushchak, Higher State Educational Institution of Ukraine «Bukovinian State Medical University» Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Assistant

Department of Pharmaceutical Botany and Pharmacognosy

Hanna Panfilova, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002

Doctor of Pharmaceutical Sciences, Professor

Department of Organization and Economics of Pharmacy

Liliia Kostyshyn, Higher State Educational Institution of Ukraine «Bukovinian State Medical University» Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Assistant

Department of Pharmaceutical Botany and Pharmacognosy

Irina Sokurenko, Institute of Advanced Training of Pharmacy Specialists National Pharmaceutical University Zakhysnykiv Ukrainy sq., 17, Kharkiv, Ukraine, 61001

PhD, Associate Professor

Department of Industrial Pharmacy and Economics

References

  1. Gobbi, P. G., Ferreri, A. J. M., Ponzoni, M., Levis, A. (2013). Hodgkin lymphoma. Critical Reviews in Oncology/Hematology, 85 (2), 216–237. doi: http://doi.org/10.1016/j.critrevonc.2012.07.002
  2. Roman, E., Smith, A. G. (2011). Epidemiology of lymphomas. Histopathology, 58 (1), 4–14. doi: http://doi.org/10.1111/j.1365-2559.2010.03696.x
  3. Vassilakopoulos, T. P., Angelopoulou, M. K. (2013). Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years. Seminars in Hematology, 50 (1), 4–14. doi: http://doi.org/10.1053/j.seminhematol.2013.02.002
  4. Salati, M., Cesaretti, M., Macchia, M., El Mistiri, M., Federico, M. (2014). epidemiological overview of hodgkin lymphoma across the Mediterranean basin. Mediterranean Journal of Hematology and Infectious Diseases, 6 (1), e2014048. doi: http://doi.org/10.4084/mjhid.2014.048
  5. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65 (2), 87–108. doi: http://doi.org/10.3322/caac.21262
  6. khajedaluee, M., Dadgarmoghaddam, M., Saeedi, R., Izadi-Mood, Z., Abrishami, M., Zamani, M. (2014). Mortality, Morbidity, Survival, and Burden of Top 9 Cancers in a Developing Country. Razavi International Journal of Medicine, 2 (3). doi: http://doi.org/10.5812/rijm.20073
  7. Khodamoradi, F., Pakzad, R., Ghoncheh, M., Sadeghi Gandomani, H., Salehiniya, H. (2018). Еpidemiology, incidence and mortality of Hodgkin’s cancer in the world and its relation with development. WCRJ, 5 (2), e1085.
  8. Mahdavifar, N., Ghoncheh, M., Pakzad, R., Momenimovahed, Z., Salehiniya, H. (2016). Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World. Asian Pacific Journal of Cancer Prevention, 17 (1), 381–386. doi: http://doi.org/10.7314/apjcp.2016.17.1.381
  9. Ansell, S. M. (2016). Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 91 (4), 434–442. doi: http://doi.org/10.1002/ajh.24272
  10. Smith, E. C., Ziogas, A., Anton-Culver, H. (2012). Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer, 118 (24), 6179–6187. doi: http://doi.org/10.1002/cncr.27684
  11. Cerhan, J. R., Slager, S. L. (2015). Familial predisposition and genetic risk factors for lymphoma. Blood, 126 (20), 2265–2273. doi: http://doi.org/10.1182/blood-2015-04-537498
  12. Linabery, A. M., Erhardt, E. B., Fonstad, R. K., Ambinder, R. F., Bunin, G. R., Ross J. A. et. al. (2014). Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: a Children’s Oncology Group study. International Journal of Cancer, 135 (6), 1454–1469. doi: http://doi.org/10.1002/ijc.28785
  13. Sergentanis, T. N., Kanavidis, P. F., Michelakos, T. F., Petridou, E. T. (2013). Cigarette smoking and risk of lymphoma in adults: a comprehensive meta-analysis on Hodgkin and non-Hodgkin disease. European Journal of Cancer Prevention, 22 (2), 131–150. doi: http://doi.org/10.1097/cej.0b013e328355ed08
  14. Lin, J., Siegartel, L. R., Lingohr-Smith, M., Menges, B., Makenbaeva, D. (2017). Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States. Clinical Therapeutics, 39 (2), 303–310. doi: http://doi.org/10.1016/j.clinthera.2016.12.010
  15. Mozaheb, Z. (2013). Epidemiology of hodgkin’s lymphoma. Health, 5 (5), 17–22. doi: http://doi.org/10.4236/health.2013.55a003
  16. Eyre, T. A., King, A. J., Collins, G. P. (2013). Classical Hodgkin’s lymphoma: past, present and future perspectives. British Journal of Hospital Medicine, 74 (11), 612–618. doi: http://doi.org/10.12968/hmed.2013.74.11.612
  17. Sullivan, R., Kowalczyk, J. R., Agarwal, B., Ladenstein, R., Fitzgerald, E., Barr, R. et. al. (2013). New policies to address the global burden of childhood cancers. The Lancet Oncology, 14 (3), e125–e135. doi: http://doi.org/10.1016/s1470-2045(13)70007-x
  18. Macalalad, A. R., McAuliffe, M., Yang, H., Kageleiry, A., Zhong, Y., Wu, E. Q. et. al. (2015). The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Current Medical Research and Opinion, 31 (3), 537–545. doi: http://doi.org/10.1185/03007995.2015.1008131
  19. Gravanis, I., Tzogani, K., Hennik, P., Graeff, P., Schmitt, P., Mueller‐Berghaus, J. et. al. (2015). The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. The Oncologist, 21 (1), 102–109. doi: http://doi.org/10.1634/theoncologist.2015-0276
  20. Kushchevyi, Ye. V., Kriachok, I. A., Martynchyk, A. V., Filonenko, K. S. (2001). Likuvannia patsiientiv z retsydyvamy ta refrakternym perebihom limfomy Khodzhkina. Rol vysokodozovoi khimioterapii ta transplantatsii hemopoetychnykh stovburovykh klityn. Klinichna onkolohiia, 1 (1), 78–88.
  21. Sivkovych, S. O., Mnishenko, V. M., Kaliuta, A. O. (2014). Limfoma Hodzhkina: suchasni aspekty diahnostyky ta likuvannia. Zb. nauk. sprats spivrobit. NMAPO imeni P. L. Shupyka, 23 (3), 667–674.
  22. Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A. et. al. (2018). Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. New England Journal of Medicine, 378 (4), 331–344. doi: http://doi.org/10.1056/nejmoa1708984
  23. Yasenchak, C. A., Tseng, W.-Y., Yap, M., Rembert, D., Patt, D. A. (2015). Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leukemia & Lymphoma, 56 (11), 3143–3149. doi: http://doi.org/10.3109/10428194.2015.1030639
  24. Krivec, D. Ya. (2001). Epidemiologiya limfogranulematoza v Ukraine v 1991–1998 gg. Onkologіya, 3 (1), 11–15.
  25. Natsionalnyi kantser-reiestr 2012–2018 rr. Available at: https://unci.org.ua/spetsialistam/nacionalnij-kancer-reyestr/ Last accessed: 04.04.2020
  26. Fang, J.-Q. (Ed.) (2017). Handbook of Medical Statistics. Sun Yat-Sen University, 835.
  27. Moskowitz, A. J., Schöder, H., Yahalom, J., McCall, S. J., Fox, S. Y., Gerecitano, J. et. al. (2015). PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised open-label, single-centre, phase 2 study. Lancet Oncol, 16 (3), 284–292.
  28. LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J. et. al. (2018). Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood, 132 (1), 40–48. doi: http://doi.org/10.1182/blood-2017-11-815183
  29. Yasenchak, C. A., Tseng, W.-Y., Yap, M., Rembert, D., Patt, D. A. (2015). Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leukemia & Lymphoma, 56 (11), 3143–3149. doi: http://doi.org/10.3109/10428194.2015.1030639

Downloads

Published

2020-04-28

How to Cite

Matushchak, M., Panfilova, H., Kostyshyn, L., & Sokurenko, I. (2020). Research of features of development of epidemiological situation on lymphogranulematosis in Ukraine. ScienceRise: Pharmaceutical Science, (2 (24), 40–50. https://doi.org/10.15587/2519-4852.2020.201570

Issue

No. 2 (24) (2020)

Section

Pharmaceutical Science

License

Copyright (c) 2020 Marta Matushchak, Hanna Panfilova, Liliia Kostyshyn, Irina Sokurenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.